Syndax Pharmaceuticals Aktie

8,60 EUR -0,15 EUR -1,71 %

08:05:07

FSE

9,92 USD -0,08 USD -0,80 %

18:51:26

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.750,30 Mio. EUR

Div. Rendite0,00%

WKNA2AFL6

ISINUS87164F1057

SymbolSNDX

Syndax Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

05.04.24PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

28.03.24PR NewswireSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

26.03.24PR NewswireSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

18.03.24PR NewswireSyndax Announces Appointment of Steven Closter as Chief Commercial Officer

01.03.24PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

27.02.24PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

26.02.24PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences

20.02.24PR NewswireSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

02.02.24PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

01.02.24PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences

05.01.24PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

02.01.24PR NewswireSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

02.01.24PR NewswireSyndax Highlights Recent Updates and Anticipated 2024 Milestones

12.12.23PR NewswireSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

11.12.23PR NewswireSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

04.12.23PR NewswireSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

01.12.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

21.11.23PR NewswireSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

07.11.23PR NewswireSyndax Announces Participation at Stifel Healthcare Conference

03.11.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

02.11.23PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

02.11.23PR NewswireSyndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

02.11.23PR NewswireSyndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

26.10.23PR NewswireSyndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

24.10.23PR NewswireSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

02.10.23PR NewswireSyndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

29.09.23PR NewswireSyndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

01.09.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

31.08.23PR NewswireSyndax Announces Participation at the Citi 18th Annual BioPharma Conference

04.08.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03.08.23PR NewswireSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

25.07.23PR NewswireSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

24.07.23PR NewswireSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

07.07.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

02.06.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24.05.23PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences

08.05.23PR NewswireSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

04.05.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

01.05.23PR NewswireSyndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

13.04.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.